New treatments and biomarkers for Chagas disease
New chemotherapy regimens and biomarkers for Chagas disease
This study is looking for ways to make current treatments for Chagas disease work better and have fewer side effects, and it invites patients with Chagas to join in testing new dosing methods for existing medications.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project ID | NIH-10896122 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for Chagas disease, a condition caused by the parasite Trypanosoma cruzi, which affects many people globally. The project aims to test new dosing regimens of existing medications, benznidazole and nifurtimox, to enhance their effectiveness and reduce side effects. By analyzing both host and parasite biomarkers, the research seeks to identify better treatment strategies that could lead to improved patient outcomes. Patients with Chagas disease may have the opportunity to participate in trials that explore these new treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for participation include individuals diagnosed with Chagas disease, particularly those in the chronic phase of the illness.
Not a fit: Patients who are asymptomatic or have not been diagnosed with Chagas disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Chagas disease.
How similar studies have performed: Previous research has shown that modifying treatment regimens can improve outcomes in other parasitic infections, suggesting potential for success in this approach.
Where this research is happening
El Paso, United States
- University of Texas El Paso — El Paso, United States (Active)
Researchers
- Principal investigator: Almeida, Igor C — University of Texas El Paso
- Study coordinator: Almeida, Igor C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.